Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Fennell DA, Hill K, Zhang M, Poile C, Ewings S, Baitei EY, Dzialo J, Nusrat N, Rogel J, Faulkner D, Ottensmeier C, Califano R, Hanna GG, Danson S, Steele N, Nye M, Johnson L, Mallard K, Lord J, Middleton C, Szlosarek P, Chan S, Darlison L, Wells-Jordan P, Richards C, Harber J, Bzura A, Spicer J, Pritchard C, Kamata T, Hahne JC, Jama M, Hollox EJ, Lester JF, Luo JL, Zhou Z, Yang H, Zhou H, Klampatsa A, Griffiths GO.
Fennell DA, et al. Among authors: griffiths go.
Nat Commun. 2025 Jul 21;16(1):6688. doi: 10.1038/s41467-025-61691-4.
Nat Commun. 2025.
PMID: 40691143
Free PMC article.
Clinical Trial.